RxDoctor Payments DataLook up a doctor →

Gulshan Uppal, MD

Neurology · Joplin, MONPI 1063725380

Payments from drug & device makers

$200,460in general payments, 2019–2025

Across 930 payments — averaging $215.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$128K
  • Biohaven Pharmaceuticals, Inc.$32K
  • Biohaven Pharmaceutical Holding Company Ltd.$22K
  • Pfizer$12K
  • Livanova USA, Inc.$1K
  • UCB, Inc.$928
  • plus $6K from 36 others

What the payments were for

  • Consulting fees$1,5251%
  • Speaking & faculty fees$177,26988%
  • Travel & lodging$6,8163%
  • Food & beverage$14,8097%
  • Education$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$200,460 in reported general payments places this provider in the 90th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$149,369
Medicare patients
631
Services billed
1,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate79$97,143
Emgality PenGalcanezumab-Gnlm74$69,688
QuliptaAtogepant38$49,121
FycompaPerampanel28$35,098
BriviactBrivaracetam13$18,324
NuedextaDextromethorphan Hbr/Quinidine11$17,031
Aimovig AutoinjectorErenumab-Aooe22$16,230
RytaryCarbidopa/Levodopa36$14,493
UbrelvyUbrogepant11$14,053
Lacosamide93$11,336
Ajovy AutoinjectorFremanezumab-Vfrm11$9,424
Carbidopa-LevodopaCarbidopa/Levodopa263$5,967
Levetiracetam189$4,090
Memantine Hcl162$4,031
Primidone243$3,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$11,842$97,14379 claims
AbbVieQulipta, Ubrelvy$127,684$63,17449 claims
Eisai Inc.Fycompa$411$35,09828 claims
UCB, Inc.Briviact$928$18,32413 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$297$18,13496 claims
Upsher-smith Laboratories LLCTopiramate$170$1,387145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 381 neurology providers in Missouri.

Other neurology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →